-
-
-
A new study finds that 60% of HIV patients on stable therapy with detectable viral replication have a rate of new HIV mutations of about 1.5 mutations per year.
-
No one is worried that a financially strapped federal government might kill Ryan White Care Act funding, but AIDS advocates say they are concerned about what will happen with the bill in a slightly different political environment this year.
-
Two potential candidates in the microbicide research pipeline are set to be examined in clinical trials, with research to focus on the safety and acceptability in healthy women and women infected with HIV.
-
While clinicians and researchers are seeing increasing numbers of HIV patients with multidrug-resistant virus, there are indications that some existing drug combinations continue to be potent against resistant virus.
-
Two separate studies have found that some types of HIV drug resistance have declined or leveled off at the same time others have increased.
-
There is new hope for a cost-efficient treatment for HIV-1 infected patients who no longer respond to protease inhibitor (PI) treatment due to multidrug resistance.
-
If HIV-1 drug resistance is found in a womans plasma, its likely the same resistance is present in her genital tract, suggesting that drug resistance among pregnant, HIV-infected women, requires further investigation, a new study shows.
-
The revised Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents was made available in late October by the National Institutes of Health. The revisions were made to improve its organization and readability.
